Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Author information

  • 1Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31343 Krak√≥w, Poland. nfpaluch@cyf-kr.edu.pl

Abstract

Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a good target for the development of new, effective and safe therapeutic drugs to treat several CNS disorders including depression and anxiety. Several potent, selective and systemically active orthosteric and allosteric ligands of specific mGlu receptor subtypes have been discovered and these have been tested as potential antidepressants in models of depression in rodents. The mGluR5 antagonists and group II mGlu receptor antagonists seem to be the most promising compounds with potential antidepressant-like activity; however, the efficacy of mGlu receptor ligands in the clinical setting is still an unanswered question.

PMID:
17107280
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk